Day: July 9, 2024

– Abiprubart Phase 2b clinical trial in Sjögren’s Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations – – Abiprubart clinical development in Sjögren’s Disease fully funded; company expects to remain cash flow positive on an annual basis – LONDON, July 09, 2024 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced that it has commenced enrollment of the Phase 2b clinical trial of abiprubart in Sjögren’s Disease. Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 (CD40 ligand) interaction. “Sjögren’s Disease is a debilitating,...

RIMOUSKI, Quebec, July 09, 2024 (GLOBE NEWSWIRE) — Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the “Company” or “Puma”) is delighted to announce a strategic property acquisition, the “Moose Brook property.” The 28 claims (608 ha) fill a gap in the 100%-owned Williams Brook property, strengthening our position in the region (Figure 1-2). Puma Exploration is the biggest landholder in Northern New Brunswick and the most active explorer in the area. “This acquisition further adds to our considerable ground position in Northern New Brunswick. Over the past four years, we’ve completed many separate transactions to consolidate a patchwork of mining claims held by many landowners. Most mining claims had seen little to no modern exploration work and had never been worked as a whole. Our exploration programs...

SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be attending the JonesHealthcare Seaside Summit 2024 being held July 14-16, 2024, in Encinitas, CA. John Bencich, CEO of Achieve, will present on Monday, July 15, 2024, at 8:45 AM PDT. Following the presentation, he will also participate in a live panel discussion titled “Introducing Disruptive Products to Established Healthcare Markets—Commercial and Regulatory Considerations” at 10:00 AM PDT. The panel will be hosted by Justin Walsh, PhD, a Healthcare Research Analyst at JonesTrading Institutional Services LLC....

— Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases — BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and an attending rheumatologist at the Penn Presbyterian Medical Center and Philadelphia VA Medical Center. “We are honored to have Dr. Laufer join our scientific advisory board. With a unique...

$3.3 Million Reallocated to Lending and Credit Line Capacity GOLDEN, Colo., July 09, 2024 (GLOBE NEWSWIRE) — SHF Holdings, Inc., d/b/a/ Safe Harbor Financial (“Safe Harbor” or the “Company”) (NASDAQ: SHFS), a leader in facilitating financial services and credit facilities to the regulated cannabis industry, announced today that it successfully exited a $3.1 million loan that was previously in default. In addition to the full repayment of the principal, Safe Harbor received $202,175 in accrued interest, all of which will be reallocated into its lending and credit line capacity. Dan Roda, Executive Vice President and Chief Operating Officer of Safe Harbor Financial, stated, “Safe Harbor has established a strong lending program that meets the financial requirements of our clients while generating appropriate risk adjusted loan interest...

ORLANDO, FL, July 09, 2024 (GLOBE NEWSWIRE) — Coda Octopus Group, Inc. (“CODA” or the “Company”) (Nasdaq: CODA), a global market leader in 4D/5D/6D imaging sonar technology for real time subsea intelligence and cutting-edge diving and communications technology, today reported that its Salt Lake City based Defense Engineering Services Business, Coda Octopus Colmek, recently received one of the orders that had been expected and delayed during the first six months of fiscal 2024. This order has a contract value of $906k and relates to one of the programs that it has been servicing for over 25 years. Annmarie Gayle, CODA’s Chairman and CEO, commented: “I am very pleased to see some of the barriers we have experienced in respect of Defense procurement budgets being removed and that we have recently received this significant order which...

SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 30, 2024. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform...

– Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Similar patents have also been granted in key markets around the world including the United States, China, and Japan -Brilaroxazine has a novel mechanism of action for treating the underlying disruption in serotonin signaling implicated in the pathogenesis of PH/PAH CUPERTINO, Calif., July 09, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today...

SINGAPORE, July 09, 2024 (GLOBE NEWSWIRE) — SAI.TECH Global Corporation (“SAI.TECH” or “SAI” or the “Company”) (NASDAQ: SAI, SAITW) announces the signing of two Memorandums of Understanding (MoU) for HEATNUC products aimed at strengthening cooperation within the small modular reactor industry. These MoUs are set to enhance SAI.TECH’s competitiveness in the Middle Eastern and international markets while increasing localization efforts in the region. The first MoU, signed with Suzhou East Instrument Technology Co., Ltd., signifies a strategic partnership focused on the export of electrical and instrumentation control system equipment for nuclear power and engineering projects. This includes Class IE K1 and K2 electrical and instrumentation control equipment, Class IE K3 equipment, non-safety-related packaged air equipment, and instrumentation...

Singapore, July 09, 2024 (GLOBE NEWSWIRE) — Nova Vision Acquisition Corp. (NASDAQ: NOVV, the “Company”), a special purpose acquisition company, announced today that Nova Pulsar Holdings Limited, the Company’s initial public offering sponsor (“Sponsor”), has deposited into the Company’s trust account (the “Trust Account”) an aggregate of $69,763.37 (representing approximately $0.045 per ordinary share issued at the Company’s initial public offering that has not been redeemed), in order to extend the period of time the Company has to complete a business combination for an additional one (1) month period, from July 10, 2024 to August 10, 2024. The Company issued a promissory note to Sponsor with a principal amount equal to the amount deposited. The promissory note bears no interest and is convertible into the Company’s units (with...